Serum methylation levels of TAC1. SEPT9 and EYA4 as diagnostic markers for early colorectal cancers: A pilot study

Biomarkers

Volumn 18, Issue 5, 2013, Pages 399-405

  Liu, Yanqun ^a   Tham, Chee Kian ^b   Ong, Simon Y K ^b   Ho, Kok Sun ^a   Lim, Jit Fong ^a   Chew, Min Hoe ^a   Lim, Che Kang ^a   Zhao, Yi ^a   Tang, Choong Leong ^a   Eu, Kong Weng ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Colorectal cancer; DNA methylation; Early diagnosis; Sensitivity and specificity; Serum

Indexed keywords

EYES ABSENT HOMOLOG 4; PROTEIN TYROSINE PHOSPHATASE; SEPTIN; SEPTIN 9; TACHYKININ; TACHYKININ 1; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE MUTATION; HUMAN; MALE; METHYLATION; PILOT STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DNA METHYLATION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; PROSPECTIVE STUDIES; ROC CURVE; SEPTINS; TRANS-ACTIVATORS; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84880551479     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.798745     Document Type: Article

References (33)

1. Ahlquist T, Ling GE, Costa VL, et al. (2008). Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset makers. Mol Cancer 7:94. doi: 10.1186/1476-4598-7-94.
2. Clark SW, Fee BE, Cleveland JL. (2002). Misexpression of the eyes absent family triggers the apoptotic program. J Biol Chem 277: 3560-7.
3. deVos T, Tetzner R, Model F, et al. 2009) Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 55 1337-46.
4. Ebert MP, Model F, Mooney S, et al. (2006). Aristalesss-like-homeobox- 4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology 131:1418-30.
5. Etzioni R, Urban N, Ramsey S, et al. (2003). The case for early detection. Nat Rev Cancer 3:243-52.
6. Fong SL, Zhang JT, Lim CK, Eu KW, Liu Y. (2009). Comparison of 7 methods for extracting cell-free DNA from serum samples of colorectal cancer patients. Clin Chem 55:587-9.
7. Grützmann R, Molnar B, Pilarsky C, et al. (2008). Sensitive detection of colorectal cancer in peripheral blood by SEPT9 methylation assay. PLoS One 3:e3759. doi: 10.1371/journal.pone.0003759.
8. Herbst A, Rahmig K, Stieber P, et al. (2011). Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. Am J Gastroenterol 106:1110-18.
9. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. (2004). Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Eng J Med 351:2704-14.
10. Jahr S, Hentze H, Englisch S, et al. (2001). DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659-65.
11. Lee BB, Lee EJ, Jung EH, et al. (2009). Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 15:6185-91.
12. Lee S, Hwang KS, Lee HJ, et al. (2004). Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab Invest 84:884-93.
13. Lee TH, Montalvo L, Chrebtow V, Busch MP. (2001). Quantitation of genomic DNA in plasma and serum samples, higher concentrations of genomic DNA found in serum than in plasma. Transfusion 41: 276-82.
14. Leung WK, To KF, Man EP, et al. (2005). Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol 100:2274-9.
15. Levin B, Lieberman DA, McFarland B, et al. (2008). Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal cancer, and the American College of Radiology. CA Cancer J Clin 58: 130-60.
16. Li M, Chen WD, Papadopoulos N, et al. (2009). Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 27:858-63.
17. Lind GE, Kleivi K, Meling GI, et al. (2006). ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol 28:259-72.
18. Liu Y, Hong Y, Zhao Y, et al. (2008). Histone H3 (lys-9) deacetylation is associated with transcriptional silencing of E-cadherin in colorectal cancer cell lines. Cancer Invest 26:575-82.
19. Lofton-Day C, Model F, DeVos T, et al. (2008). DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 54:414-23.
20. Lui YY, Chik KW, Chiu RW, et al. (2002). Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 48:421-7.
21. Luo YX, Chen DK, Song SX, et al. (2011). Aberrant methylation of genes in stool samples as diagnostic biomarkers for colorectal cancer or adenomas: a meta-anlaysis. Int J Clin Pract 65: 1313-20.
22. Macdonald JS. (1999). Carcinoembryonic antigen screening: Pros and cons. Semin Oncol 26:556-60.
23. Mori Y, Cai K, Cheng Y, et al. (2006). A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology 131:797-808.
24. Morikawa T, Kato J, Yamaji Y, et al. (2005). A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 129:422-48.
25. Nakayama H, Hibi K, Taguchi M, et al. (2002). Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. Cancer Lett 188:115-19.
26. Rameshwar P, Gascon P. (1996). Induction of negative hematopoietic regulators by neurokinin-A in bone marrow stroma. Blood 88: 98-106.
27. Rashid A, Shen L, Morris JS, et al. (2001). CpG island methylation in colorectal adenomas. Am J Pathol 159:1129-35.
28. Shen L, Kondo Y, Rosner GL, et al. (2005). MGMT promoter methylation and field effect in sporadic colorectal cancer. J Natl Cancer Inst 97:1330-38.
29. Smith RA, Cokkinides V, Eyre HJ. (2006). American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin 56:11-25.
30. Summers T, Langan RC, Nissan A, et al. (2013). Serum-based DNA methylation biomarkers in colorectal cancer: potential for screening and early detection. J Cancer 4:210-16.
31. Warren JD, Xiong W, Bunker AM, et al. (2011). Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med 9:133. doi: 10.1186/1741-7015-9-133.
32. Woolf SH. (2004). A smarter strategy? Reflections on DNA screening for colorectal cancer. N Engl J Med 351:2755-8.
33. Zou HZ, Yu BM, Wang ZW, et al. (2002). Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res 8:188-91.